The Burden of the Daily Pill
For millions of people living with HIV, the daily ritual of taking antiretroviral therapy (ART) is more than just a medical necessity; it is a constant reminder of a chronic condition. For adolescents, this burden is often magnified. Teenagers navigate a complex world of social transitions, self-image development, and the desire for privacy. In this context, the requirement to take a pill at the same time every day can lead to ‘pill fatigue,’ accidental disclosure of their status to peers, and significant psychological stress. In many cases, these challenges result in poor adherence, which risks treatment failure and the development of drug-resistant viral strains. However, a landmark clinical trial is offering a glimpse into a future where the daily pill is no longer the only option. The IMPAACT 2017/MOCHA study has provided robust evidence that long-acting injectable treatments are not only feasible for adolescents but are also safe and highly effective.
